New Initiative— “Live Well. Do Tell.™”—Aims to
Support People with Parkinson’s
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today unveiled the “Live
Well. Do Tell.” initiative for the Parkinson’s disease community.
Its goal is to encourage the community to improve conversations
about Parkinson’s symptoms among the circle of care, including
people with Parkinson’s (PwPs), care partners, advocacy and
healthcare professionals. The first output of the initiative -- the
Statement of Need -- was developed based on learnings and insights
from a multi-disciplinary steering committee of leaders in the
Parkinson’s community who collaborated to discuss unmet needs in
understanding and communicating about Parkinson’s symptoms.
“Research suggests that PwPs may not discuss the full range of
their symptoms or their impact with their physicians and care
partners for various reasons,” said Matthew Stern, M.D., Professor
Emeritus of Neurology, Perelman School of Medicine, University of
Pennsylvania and Steering Committee Member. “Clear and effective
communication between PwPs and physicians is critical to better
understand important aspects of a PwP’s well-being.”
“Acorda is dedicated to those living with neurological
conditions. It is a privilege to serve the Parkinson’s community
through the launch of this initiative, which aims to address the
many barriers PwPs and their care partners face in communicating
about Parkinson’s symptoms, including OFF periods,” said Ron Cohen,
M.D., Acorda’s President and CEO. “We are proud to have partnered
with many members of this community on this initiative to find the
tools to understand and discuss Parkinson’s symptoms.”
About “Live Well. Do Tell.”
“Live Well. Do Tell.” is an initiative, created by Acorda with
input from a multi-disciplinary steering committee of Parkinson’s
leaders and experts, to generate a shared understanding, build
awareness and develop an approach to bridge communication gaps
among PwPs, care partners, advocacy and healthcare professionals to
inspire a movement for optimal conversations.
The “Live Well. Do Tell.” Statement of Need includes six actions
for the Parkinson’s community to help identify and communicate
about their symptoms. These actions are based on insights from the
steering committee as well as research conducted by Acorda and
third parties.
The steering committee included PwPs, care partners, movement
disorder specialists, a nurse practitioner and representatives from
key advocacy groups, including the American Parkinson’s Disease
Association, Caregiver Action Network, Davis Phinney Foundation,
The Michael J. Fox Foundation, Parkinson’s Foundation and the
Parkinson & Movement Disorder Alliance.
“Like many people who live with Parkinson’s, I struggle with the
reality of my Parkinson’s symptoms every day,” said Steve DeWitte,
Founder and a member of the Board of Directors for the Connecticut
Advocates for Parkinson’s (CAP) and Steering Committee Member. “New
resources and tools that help us talk with our circle of care about
the impact of re-emerging symptoms are necessary.”
About Parkinson’s and OFF Periods
Approximately one million people in the U.S. are diagnosed with
Parkinson’s;1 OFF periods are experienced by approximately 350,000
in the U.S.1,2,3
Parkinson’s is a progressive neurodegenerative disorder
resulting from the gradual loss of certain neurons responsible for
producing dopamine. It causes a range of symptoms including
impaired movement, muscle stiffness and tremors.4 As Parkinson’s
progresses, people will experience OFF periods, which are
characterized by the re-emergence of Parkinson’s symptoms.5,6 This
re-emergence can occur even when an individual’s treatment regimen
has been optimized.7
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biopharmaceutical
company focused on developing therapies that restore function and
improve the lives of people with neurological disorders. Acorda has
a pipeline of novel neurological therapies addressing a range of
disorders, including Parkinson’s disease and multiple sclerosis.
Acorda markets two FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: the ability to realize the benefits
anticipated from acquisitions, among other reasons because acquired
development programs are generally subject to all the risks
inherent in the drug development process and our knowledge of the
risks specifically relevant to acquired programs generally improves
over time; we may need to raise additional funds to finance our
operations and may not be able to do so on acceptable terms; our
ability to successfully market and sell Ampyra (dalfampridine)
Extended Release Tablets, 10 mg in the U.S., which will likely be
materially adversely affected by the March 2017 court decision in
our litigation against filers of Abbreviated New Drug Applications
to market generic versions of Ampyra in the U.S.; the risk of
unfavorable results from future studies of Inbrija (levodopa
inhalation powder) or from our other research and development
programs, or any other acquired or in-licensed programs; we may not
be able to complete development of, obtain regulatory approval for,
or successfully market Inbrija or any other products under
development; third party payers (including governmental agencies)
may not reimburse for the use of Ampyra, Inbrija or our other
products at acceptable rates or at all and may impose restrictive
prior authorization requirements that limit or block prescriptions;
the occurrence of adverse safety events with our products; the
outcome (by judgment or settlement) and costs of legal,
administrative or regulatory proceedings, investigations or
inspections, including, without limitation, collective,
representative or class action litigation; competition; failure to
protect our intellectual property, to defend against the
intellectual property claims of others or to obtain third party
intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements
could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
______________________________1 Parkinson’s Foundation.
Statistics. Available from:
http://www.parkinson.org/Understanding-Parkinsons/Causes-and-Statistics/Statistics.
Accessed November 2017.2 Ahlskog JE, Muenter MD. Mov Disord.
2001;16(3):448-458.3 Decision Resources. Parkinson’s Disease
(Report: January 2015). 2015.4 Parkinson’s Foundation. What is
Parkinson’s?. Available from:
http://www.parkinson.org/understanding-parkinsons/what-is-parkinsons.
Accessed January 2018.5 Olanow CW, Stern MB, Sethi K. Neurology.
2009;72(21 Suppl 4):S1-136.6 Obeso JA, Rodriguez-Oroz MC, Chana P,
et al. Neurology. 2000;55(11 Suppl 4):S13-20.7 Stocchi
F. Expert Opin Pharmacother. 2006;7(10):1399-1407.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180314005041/en/
Media:Acorda Therapeutics, Inc.Gail Cohen,
914-326-5162gcohen@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Sep 2023 to Sep 2024